2023
DOI: 10.1021/acs.cgd.2c01421
|View full text |Cite
|
Sign up to set email alerts
|

Polymorph Screening of the Antitumor Drug Ripretinib─Selective Preference of Dimer Synthons

Abstract: Ripretinib is commercialized as a medication to treat patients suffering from advanced gastrointestinal stromal tumor. The USFDA-approved drug (2020) is highly water-insoluble and belongs to the biopharmaceutics classification system (BCS) class II category. Solid form screening was performed to initiate its structural landscape and establish thermodynamic relationship between the crystalline forms. This resulted in two anhydrous polymorphs (Forms 1 and 2), one hydrate, and a series of solvates with acetone, e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
4
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
8

Relationship

1
7

Authors

Journals

citations
Cited by 8 publications
(5 citation statements)
references
References 42 publications
1
4
0
Order By: Relevance
“…The homodimer formation may be suggested to be an extended domain formation, which helps in better packing arrangements through a gain in considerable amounts of energy. Polymorphic systems based on different homodimers are available in the literature …”
Section: Resultssupporting
confidence: 93%
“…The homodimer formation may be suggested to be an extended domain formation, which helps in better packing arrangements through a gain in considerable amounts of energy. Polymorphic systems based on different homodimers are available in the literature …”
Section: Resultssupporting
confidence: 93%
“…To answer these questions, crystals were grown in a variety of apolar, polar aprotic, and polar protic solvents. Solvatomorphism was observed in compounds 1 and 2 , and polymorphism was revealed in compounds 3 and 4 . The dominant synthon observed in all four molecules is the LLD.…”
Section: Introductionmentioning
confidence: 95%
“…It is very important for pharmaceutical companies to find the most stable and suitable polymorphic form before formulation and commercialization in order to avoid setbacks in the later stages of drug development. 4 Evaluation and control of impurities during synthesis of a drug is very challenging for the development team as impurities may cause serious side effects to the patients and their presence is generally not recommended. 5 Recently, at least ten drugs such as ranitidine, irbesartan, losartan, metformin, nizatidine, rifampin, quinapril, sitagliptin, varenicline and valsartan were recalled from the market due to carcinogenic nitrosoamine impurities.…”
Section: Introductionmentioning
confidence: 99%